DESLORATADINE HEMISULFATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	2C19H19ClN2.H2O4S
Molecular Weight	719.72
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OS(O)(=O)=O.ClC1=CC2=C(C=C1)C(=C3CCNCC3)C4=C(CC2)C=CC=N4.ClC5=CC6=C(C=C5)C(=C7CCNCC7)C8=C(CC6)C=CC=N8

InChI

InChIKey=BFUKZAZVGNXTDM-UHFFFAOYSA-N

InChI=1S/2C19H19ClN2.H2O4S/c2*20-16-5-6-17-15(12-16)4-3-14-2-1-9-22-19(14)18(17)13-7-10-21-11-8-13;1-5(2,3)4/h2*1-2,5-6,9,12,21H,3-4,7-8,10-11H2;(H2,1,2,3,4)

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11243504
Curator's Comment: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf

Desloratadine is an active, descarboethoxy metabolite of loratadine. It acts by selective inhibition of H1 histamine receptor and thus provides relief to patients with allergic rhinitis and chronic idiopathic urticaria. Desloratadine was approved by FDA and it is currently marketed under the name Clarinex (among the others).

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Histamine H1 receptor 315 Target ID: CHEMBL231 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf	Antagonist 2778		0.87 nM [Ki]

Conditions

Condition	Modality	Highest Phase	Product
Seasonal allergic rhinitis 64 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf	Palliative	Approved 8429	CLARINEX Approved Use Desloratadine Tablets are indicated for: Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, Chronic Idiopathic Urticaria. Launch Date 2001
Perennial allergic rhinitis 47 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf	Palliative	Approved 8429	CLARINEX Approved Use Desloratadine Tablets are indicated for: Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, Chronic Idiopathic Urticaria. Launch Date 2001
Chronic idiopathic urticaria 11 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf	Palliative	Approved 8429	CLARINEX Approved Use Desloratadine Tablets are indicated for: Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, Chronic Idiopathic Urticaria. Launch Date 2001

C_max

Value	Dose	Co-administered	Analyte	Population
4 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf	5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DESLORATADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
56.9 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf	5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DESLORATADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
27 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf	5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DESLORATADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
84.5% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf	5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DESLORATADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
1.25 mg 1 times / day steady, oral Dose: 1.25 mg, 1 times / day Route: oral Route: steady Dose: 1.25 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021300s000_Clarinex_MedR.pdf Page: p. 25	unhealthy, 2-11 years n = 48 Health Status: unhealthy Age Group: 2-11 years Sex: M+F Population Size: 48 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021300s000_Clarinex_MedR.pdf Page: p. 25	Disc. AE: Somnolence, Abdominal pain... AEs leading to discontinuation/dose reduction: Somnolence (1 patient) Abdominal pain (1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021300s000_Clarinex_MedR.pdf Page: p. 25
45 mg 1 times / day multiple, oral Highest studied dose Dose: 45 mg, 1 times / day Route: oral Route: multiple Dose: 45 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21165lbl.pdf	healthy, adult Health Status: healthy Age Group: adult Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21165lbl.pdf	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21165lbl.pdf

AEs

AE	Significance	Dose	Population
Abdominal pain	1 patient Disc. AE	1.25 mg 1 times / day steady, oral Dose: 1.25 mg, 1 times / day Route: oral Route: steady Dose: 1.25 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021300s000_Clarinex_MedR.pdf Page: p. 25	unhealthy, 2-11 years n = 48 Health Status: unhealthy Age Group: 2-11 years Sex: M+F Population Size: 48 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021300s000_Clarinex_MedR.pdf Page: p. 25
Somnolence	1 patient Disc. AE	1.25 mg 1 times / day steady, oral Dose: 1.25 mg, 1 times / day Route: oral Route: steady Dose: 1.25 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021300s000_Clarinex_MedR.pdf Page: p. 25	unhealthy, 2-11 years n = 48 Health Status: unhealthy Age Group: 2-11 years Sex: M+F Population Size: 48 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021300s000_Clarinex_MedR.pdf Page: p. 25

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737	inhibitor 1767	substrate 1217 inhibitor 1852	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1524 CYP2C8 911 CYP2C19 1478 CYP2B6 810 CYP3A4/5 278 UGT1A1 204 UGT1A3 84 UGT1A4 77 UGT1A6 108 UGT1A9 116 UGT2B7 146 UGT2B10 25 UGT2B15 64 UGT2B17 18 UGT1A7 21 UGT1A8 36 UGT1A10 32 UGT2B4 19 P-gp 1461	CYP1A2 1054 CYP2B6 664 CYP1A1 349 CYP2C19 991 UGT2B10 127 P-gp 1537

Drug as perpetrator

Target	Modality	Activity
CYP1A2 1692	inhibitor 3277 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,5	no
CYP2C19 1553	inhibitor 3277 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,5	no
CYP2C8 965	inhibitor 3277 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,5	no
CYP2C9 1819	inhibitor 3277 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,5	no
UGT1A1 254	inhibitor 3277 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	no
UGT1A3 93	inhibitor 3277 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	no
UGT1A4 80	inhibitor 3277 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	no
UGT1A6 141	inhibitor 3277 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	no
UGT1A7 23	inhibitor 3277 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	no
UGT1A8 48	inhibitor 3277 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	no
UGT1A9 121	inhibitor 3277 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	no
UGT2B15 64	inhibitor 3277 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	no
UGT2B7 157	inhibitor 3277 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	no
P-gp 1650	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/11454724/	not significant [IC50 43 uM]
UGT2B10 27	inhibitor 3277 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	strong [Ki 1.3 uM]
CYP2B6 1001	inhibitor 3277 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,5	weak [Inhibition 10 uM]
CYP2D6 1891	inhibitor 3277 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,5	weak [Inhibition 10 uM]
CYP3A4/5 335	inhibitor 3277 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,5	weak [Inhibition 10 uM]
UGT1A10 41	inhibitor 3277 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	weak [Inhibition 10 uM]
UGT2B17 20	inhibitor 3277 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	weak [Inhibition 10 uM]
UGT2B4 19	inhibitor 3277 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	weak [Inhibition 10 uM]

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP1A1 349	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-165_Clarinex_biopharmr_P1.pdf#page=19 Page: 19.0	likely
CYP1A2 1054	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-165_Clarinex_biopharmr_P1.pdf#page=10 Page: 10.0	likely
CYP2B6 664	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-165_Clarinex_biopharmr_P1.pdf#page=10 Page: 10.0	likely
CYP2C19 991	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-165_Clarinex_biopharmr_P1.pdf#page=19 Page: 19.0	likely	no (pharmacogenomic study) Comment: pharmacogenotype 2C19 does not correlate with systemic exposure Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-165_Clarinex_biopharmr_P1.pdf#page=19 Page: 19.0
CYP2D6 1217	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-165_Clarinex_biopharmr_P1.pdf#page=10 Page: 10.0	likely	no (pharmacogenomic study) Comment: lack of correlation in between 2D6 genotype and 3-OH DCL formation Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-165_Clarinex_biopharmr_P1.pdf#page=10 Page: 10.0
CYP3A4 1737	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-165_Clarinex_biopharmr_P1.pdf#page=10; https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-165_Clarinex_biopharmr_P1.pdf#page=33 Page: 10.0	likely	weak (co-administration study) Comment: Coadministration of ketonconazole, mean drug Cmax and AUC0-24 values at steady state were increased by 29-45% and 21-39%, respectively; Coadministration with erythromycin, mean drug Cmax and AUC 0-24 at steady state were increased by 24% and 14%, respectively. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-165_Clarinex_biopharmr_P1.pdf#page=10; https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-165_Clarinex_biopharmr_P1.pdf#page=33 Page: 10.0
UGT2B10 127	substrate 3367 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 1.0	yes
P-gp 1537	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388404/	yes	weak (co-administration study) Comment: Coadministration of ketonconazole, mean drug Cmax and AUC0-24 values at steady state were increased by 29-45% and 21-39%, respectively; Coadministration with erythromycin, mean drug Cmax and AUC 0-24 at steady state were increased by 24% and 14%, respectively. Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388404/

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://pubmed.ncbi.nlm.nih.gov/11243504/#:~:text=Preclinical%20studies%20also%20show%20that,in%20preclinical%20and%20clinical%20studies.

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:291342	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:291342
ChemicalBook	CB3462564	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB3462564
MolPort	MolPort-000-883-875	https://www.molport.com/shop/molecule-link/MolPort-000-883-875
Selleck Chemicals	desloratadine	http://www.selleckchem.com/products/desloratadine.html
ZINC	ZINC000000001261	http://zinc15.docking.org/substances/ZINC000000001261
eMolecules	877481	https://www.emolecules.com/cgi-bin/more?vid=877481

PubMed

Title	Date	PubMed
Second-generation antihistamines in asthma therapy: is there a protective effect?	2002	14720073
Poor sleep and daytime somnolence in allergic rhinitis: significance of nasal congestion.	2002	14720057
Advances in allergy management.	2002	12492727
The new antihistamines--desloratadine and levocetirizine: a review.	2002 Dec	12851991
[The place of new antihistamines in allergy management. Apropos of desloratadine].	2002 Dec	12575624
Comparative pharmacology of H1 antihistamines: clinical relevance.	2002 Dec 16	12517581
Treatment of allergic rhinitis.	2002 Dec 16	12517578
Desloratidine for the treatment of chronic urticaria.	2002 Oct	12548327
Severe hepatotoxicity after application of desloratadine and fluconazole.	2003	12975558
Desloratadine: an update of its efficacy in the management of allergic disorders.	2003	12962522
Chronic urticaria: a role for newer immunomodulatory drugs?	2003	12688835
Comparative effects of desloratadine versus montelukast on asthma symptoms and use of beta 2-agonists in patients with seasonal allergic rhinitis and asthma.	2003 Apr	12740532
Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial.	2003 Apr	12664016
Pharmacokinetic properties of single-dose loratadine and ambroxol alone and combined in tablet formulations in healthy men.	2003 Aug	14512130
Efficacy of azelastine nasal spray in patients with an unsatisfactory response to loratadine.	2003 Aug	12952117
Studies on performance and sleepiness with the H1-antihistamine, desloratadine.	2003 Aug	12924753
Assessing satisfaction with desloratadine and fexofenadine in allergy patients who report dissatisfaction with loratadine.	2003 Aug 13	12917016
Gateways to clinical trials.	2003 Dec	14735233
Interactions of olopatadine and selected antihistamines with model and natural membranes.	2003 Dec	14704897
Comparative in vivo bioactivity of modern H1-antihistamines on AMP challenge in atopic asthma.	2003 Feb	12589354
Desloratadine: a nonsedating antihistamine.	2003 Feb	12549956
The effect of ketotifen on inflammatory markers in allergic conjunctivitis: an open, uncontrolled study.	2003 Jan 6	12515585
Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo- and active-controlled trial.	2003 Jul	12946545
Pharmacokinetics of loratadine and its active metabolite descarboethoxyloratadine in healthy Chinese subjects.	2003 Jul	12852841
Desloratadine inhibits allergen-induced airway inflammation and bronchial hyperresponsiveness and alters T-cell responses in murine models of asthma.	2003 Jul	12847492
Validation of a sensitive and automated 96-well solid-phase extraction liquid chromatography-tandem mass spectrometry method for the determination of desloratadine and 3-hydroxydesloratadine in human plasma.	2003 Jul 25	12860030
[Safety of new antihistamines].	2003 Jun	14524292
[Clinical aspects of anti-inflammatory action of antihistamines].	2003 Jun	14524290
The effects of histamine and leukotriene receptor antagonism on nasal mannitol challenge in allergic rhinitis.	2003 Jun	12814463
Effects of mediator antagonism on mannitol and adenosine monophosphate challenges.	2003 Jun	12801313
Comparison of the effects of desloratadine 5-mg daily and placebo on nasal airflow and seasonal allergic rhinitis symptoms induced by grass pollen exposure.	2003 Jun	12757447
Gateways to clinical trials. March 2003.	2003 Mar	12731460
Double-stranded RNA viruses in a mycocinogenic strain of Cystofilobasidium infirmominiatum.	2003 Mar	12702247
Decongestant effects of antihistamines: a class effect?	2003 Mar	12642858
Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis.	2003 Mar	12642846
P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists.	2003 Mar	12584158
First do no harm: managing antihistamine impairment in patients with allergic rhinitis.	2003 May	12743547
[Multicenter study of the effectiveness and tolerability of desloratadine in seasonal allergic rhinitis].	2003 May 25	12847854
Desloratadine for allergic rhinitis.	2003 Nov 15	14655812
Loratadine, desloratadine and pregnancy: don't use, risk of hypospadias.	2003 Oct	14619900
A comparison of the effect of diphenhydramine and desloratadine on vigilance and cognitive function during treatment of ragweed-induced allergic rhinitis.	2003 Oct	14582817
Efficacy and safety profile of fexofenadine HCl: a unique therapeutic option in H1-receptor antagonist treatment.	2003 Oct	14530791
Comparison of the effects of desloratadine and levocetirizine on histamine-induced wheal, flare and itch in human skin.	2003 Oct	14520518
Twenty-four-hour activity and consistency of activity of levocetirizine and desloratadine in the skin.	2003 Oct	12968983
Reliable and specific high-performance liquid chromatographic method for simultaneous determination of loratadine and its metabolite in human plasma.	2003 Oct 25	14552827
[Modern antihistaminics against allergic rhinitis. Better breathing without side effects].	2003 Oct 30	14655512
Inhibition of cold urticaria by desloratadine.	2004 Jan	14754651
Anti-inflammatory activity of H1-receptor antagonists: review of recent experimental research.	2004 Jan	14741075
Gateways to clinical trials.	2004 Jan-Feb	14988742
High-performance liquid chromatographic method for the bioequivalence evaluation of desloratadine fumarate tablets in dogs.	2004 Mar 10	15019035

Patents

Sample Use Guides

In Vivo Use Guide

Adults and Adolescents 12 Years of Age and Over: take 5 mg tablet once daily. Children 6 to Years of Age: take 2.5 mg tablet once daily. Children 12 Months to 5 Years of Age: take 1.25 mg tablet once daily. Children 6 to 11 Months of Age: 1 mg tablet once daily.

Route of Administration: Oral

In Vitro Use Guide

Nasal epithelial cells (activated by 1 uM of histamine) were treated with 10 uM of desloratadine and the inhibitory activity of the drug on expression of ICAM-1 and HLA-DR was studied.

Name

Type

Language

DESLORATADINE HEMISULFATE

Common Name

English

Code System Code Type Description

FDA UNII

WGA590NHUY

Created by admin on Sat Dec 16 03:07:49 GMT 2023 , Edited by admin on Sat Dec 16 03:07:49 GMT 2023

PRIMARY

PUBCHEM

76960496

Created by admin on Sat Dec 16 03:07:49 GMT 2023 , Edited by admin on Sat Dec 16 03:07:49 GMT 2023

PRIMARY

EVMPD

SUB177343

Created by admin on Sat Dec 16 03:07:49 GMT 2023 , Edited by admin on Sat Dec 16 03:07:49 GMT 2023

PRIMARY

SMS_ID

100000163223

Created by admin on Sat Dec 16 03:07:49 GMT 2023 , Edited by admin on Sat Dec 16 03:07:49 GMT 2023

PRIMARY

ACTIVE MOIETY


					FVF865388R

Desloratadine

SUBSTANCE RECORD


					WGA590NHUY

DESLORATADINE HEMISULFATE

Details

SMILES

InChI

DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/11243504Curator's Comment: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf

CNS Activity

Approval Year

Targets

Conditions

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Cmax

AUC

T1/2

Funbound

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Tox targets

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11243504
Curator's Comment: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf

C_max

T_1/2

F_unbound

Drug as perpetrator